Stoke Therapeutics Reports Steep Q1 Revenue Decline and Net Loss, Secures $80.7M in ATM Sales
STOK has more than doubled off its 52-week low of $8.51.
Summary
Stoke Therapeutics reported a 96.1% year-over-year revenue decline and a net loss of $50.0 million for Q1 2026, while securing $80.7 million in ATM sales and extending its cash runway into 2028.
Key Events · Earnings and Guidance · STOK
-
Q1 2026 Financial Results
Revenue for Q1 2026 plummeted 96.1% to $6.2 million from $158.6 million in Q1 2025. The company reported a net loss of $50.0 million, a significant reversal from the net income of $112.9 million in the prior year period.
-
ATM Capital Raise
Stoke Therapeutics generated $80.7 million in net proceeds during Q1 2026 through its controlled equity offering sales agreement, part of an existing ATM program.
-
Liquidity and Cash Runway
The company's cash, cash equivalents, and marketable securities totaled $411.0 million as of March 31, 2026, which is expected to fund operations into 2028.
-
Clinical Program Updates
Positive 4-year longitudinal data from open-label extension studies for zorevunersen in Dravet syndrome showed durable reductions in convulsive seizure frequency and continuous improvements in cognition and behavior. The first patient was dosed in the Phase 1 OSPREY study for STK-002 in Autosomal Dominant Optic Atrophy (ADOA).
Analysis · STOK · Life Sciences
Stoke Therapeutics' Q1 2026 financial results show a significant downturn, with revenue plummeting 96.1% year-over-year and a substantial shift from net income to a net loss. This severe financial performance is the primary driver of the negative sentiment. However, the company successfully raised $80.7 million through its at-the-market (ATM) offering, providing crucial liquidity and extending its cash runway into 2028. This capital raise, while dilutive, is a necessary step for continued operations. The company also provided positive updates on its clinical programs, including 4-year data for zorevunersen in Dravet syndrome and the initiation of a Phase 1 study for STK-002 in ADOA, alongside a new long-term lease for expanded headquarters, indicating ongoing operational growth and commitment to its pipeline.
At the time of this filing, STOK was trading at $33.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $8.51 to $40.22. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.